TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $22.00 at The Goldman Sachs Group

TG Therapeutics (NASDAQ:TGTX - Free Report) had its price objective hoisted by The Goldman Sachs Group from $20.00 to $22.00 in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company's stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright restated a "buy" rating and issued a $49.00 price objective on shares of TG Therapeutics in a research report on Wednesday, September 18th. B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $37.67.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $1.50 during trading hours on Tuesday, hitting $25.86. The stock had a trading volume of 3,955,272 shares, compared to its average volume of 3,648,657. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -258.00 and a beta of 2.19. TG Therapeutics has a one year low of $9.81 and a one year high of $26.99. The company has a 50 day simple moving average of $23.51 and a two-hundred day simple moving average of $20.17. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $83.90 million for the quarter, compared to analysts' expectations of $81.68 million. During the same quarter in the previous year, the firm earned $0.73 earnings per share. TG Therapeutics's quarterly revenue was down 49.4% compared to the same quarter last year. Research analysts forecast that TG Therapeutics will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TGTX. Marshall Wace LLP bought a new position in shares of TG Therapeutics during the second quarter valued at about $36,501,000. Hood River Capital Management LLC purchased a new stake in TG Therapeutics during the 1st quarter valued at about $22,420,000. Principal Financial Group Inc. grew its position in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in TG Therapeutics in the 2nd quarter worth approximately $10,423,000. Finally, Assenagon Asset Management S.A. bought a new stake in TG Therapeutics in the second quarter valued at approximately $8,698,000. Institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.